Lineus Medical

Lineus Medical, maker of SafeBreak Vascular, has seen breakthrough clinical results at multiple hospital systems across the U.S. that validate the clinical and health-economic value proposition for SafeBreak, the first breakaway device for IV lines.

Lineus Medical is pleased to announce a new distribution agreement with DIMA MedTech, marking the company's entry into the Italian market and further expanding its growing presence across Europe after receiving CE mark in December of 2025.

Lineus Medical, a leader in vascular access innovation and maker of SafeBreak® Vascular, the first breakaway device for IV lines, today announced the renewal of its agreement with Vizient, one of the nation's largest group purchasing organization (GPO).

Lineus Medical, a leader in vascular access innovation and maker of SafeBreak® Vascular, the first breakaway device for IV lines, announced completion of a strategic recapitalization with KMF Investments.

Lineus Medical announces that SafeBreak® Vascular has been added to Alliant Purchasing's contract portfolio, expanding access to the breakaway IV technology across Alliant's extensive healthcare network.

Lineus Medical is now officially registered in the United Kingdom, enabling the company to begin distributing SafeBreak® Vascular within the UK healthcare market.

Lineus Medical, the leader in vascular access innovation, has been awarded a U.S. patent for SafeBreak® Vascular Generation 2, the next evolution of the company's flagship breakaway device.

Lineus Medical has obtained CE Mark certification for its flagship product, SafeBreak® Vascular, the only breakaway device for IV lines clinically proven to reduce multiple IV complications.1 With this certification, SafeBreak Vascular is now cleared...

Lineus Medical is pleased to announce a new distribution agreement with Venture Medical, a 100% New Zealand–owned medical supplier based in Auckland.

Lineus Medical has been granted five additional international patents for its flagship product, SafeBreak® Vascular, in Korea, Brazil, Australia, India, and China.